CARB-X is awarding Vedanta Biosciences, of Cambridge, MA, USA, up to $5.8 million in non-dilutive funding
CARB-X is awarding Vedanta Biosciences, of Cambridge, MA, USA, up to $5.8 million in non-dilutive funding, with the possibility of $3.5 million more if certain project milestones are met, to develop a new category of oral therapeutics designed to restore a patient’s healthy microbiota so that it can fight multi-drug-resistant bacteria.
The funding will support the development of VE707, Vedanta’s preclinical human microbiome program. VE707 is designed to restore a healthy microbiota as well as prevent infection and colonization recurrence of several multi-drug resistant organisms (MDRO) which are responsible for hundreds of thousands of hospital-acquired infections each year in the United States and Europe. This is the second Vedanta project that has been selected by CARB-X for funding and support.
Global Ambassador Network
Welcome at the AMR Insights Ambassador Network!
The AMR Insights Ambassador Network is a growing, distinctive group of professionals who stand out for their commitment, willingness to cooperate and open attitude to combat Antimicrobial resistance (AMR).